NZ209962A - Stable, crystalline form of prazosin hydrochloride - Google Patents

Stable, crystalline form of prazosin hydrochloride

Info

Publication number
NZ209962A
NZ209962A NZ209962A NZ20996284A NZ209962A NZ 209962 A NZ209962 A NZ 209962A NZ 209962 A NZ209962 A NZ 209962A NZ 20996284 A NZ20996284 A NZ 20996284A NZ 209962 A NZ209962 A NZ 209962A
Authority
NZ
New Zealand
Prior art keywords
prazosin hydrochloride
stable
crystalline
anhydrous
prazosin
Prior art date
Application number
NZ209962A
Other languages
English (en)
Inventor
S O E Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of NZ209962A publication Critical patent/NZ209962A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NZ209962A 1984-06-25 1984-10-23 Stable, crystalline form of prazosin hydrochloride NZ209962A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
NZ209962A true NZ209962A (en) 1987-06-30

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ209962A NZ209962A (en) 1984-06-25 1984-10-23 Stable, crystalline form of prazosin hydrochloride

Country Status (17)

Country Link
US (2) US4739055A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6115881A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT389117B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU566814B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE900925A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH661045A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3429415A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI79107C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2567124B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2160861B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL73267A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1224142B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU85616A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8403250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ209962A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT79411B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA85910B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683760D1 (de) * 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体2―〔4―(2―フロイル)ピペラジン―1―イル〕―4―アミノ―6,7―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
CN101293888B (zh) * 2001-02-24 2013-09-25 勃林格殷格翰制药两合公司 黄嘌呤衍生物、其制法及其作为药物组合物的用途
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
UA97244C2 (en) 2006-05-04 2012-01-25 Берингер Ингельхайм Интернациональ Гмбх Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
JP5843855B2 (ja) 2010-06-24 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病療法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969375A (en) * 1961-01-24 Certification of correction
DE156532C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
BE427505A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Also Published As

Publication number Publication date
GB2160861A (en) 1986-01-02
US4873330A (en) 1989-10-10
PT79411A (en) 1984-11-01
LU85616A1 (fr) 1985-06-04
DE3429415A1 (de) 1986-01-02
JPS6115881A (ja) 1986-01-23
IT8423292A0 (it) 1984-10-24
CH661045A5 (de) 1987-06-30
FI842544A0 (fi) 1984-06-25
GB2160861B (en) 1987-11-18
GB8424999D0 (en) 1984-11-07
DE3429415C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-05-03
JPH0481993B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-12-25
IL73267A (en) 1988-06-30
ZA85910B (en) 1985-09-25
ATA344184A (de) 1989-03-15
FR2567124B1 (fr) 1990-09-21
FR2567124A1 (fr) 1986-01-10
AU3451084A (en) 1986-01-02
AU566814B2 (en) 1987-10-29
PT79411B (en) 1986-09-15
AT389117B (de) 1989-10-25
US4739055A (en) 1988-04-19
BE900925A (fr) 1985-02-15
NL8403250A (nl) 1986-01-16
FI79107C (fi) 1989-11-10
IT1224142B (it) 1990-09-26
FI842544L (fi) 1985-12-26
IL73267A0 (en) 1985-01-31
FI79107B (fi) 1989-07-31

Similar Documents

Publication Publication Date Title
NZ209962A (en) Stable, crystalline form of prazosin hydrochloride
US4721723A (en) Anti-depressant crystalline paroxetine hydrochloride hemihydrate
US4816455A (en) Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation
EP1956015B2 (en) Polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
KR20010013615A (ko) 4-페닐피페리딘 화합물
KR20070105299A (ko) 레트로졸의 제조를 위한 개선된 방법
ITMI20011726A1 (it) Forme polimorfe della lercanidipina cloridrato
KR20110017936A (ko) 퀴놀린 화합물의 결정형 및 그의 제조 방법
US20080269315A1 (en) Crystalline form
EP1345903A1 (en) Crystalline forms of cerivastatin sodium
US6197998B1 (en) Process for producing N-glycyltyrosine and its crystal structure
WO2000078729A1 (en) Crystalline forms of lansoprazole
US20050272775A1 (en) Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
FI110777B (fi) Menetelmä 7-[7-(S)-amino-5-atsaspiro[2.4]heptan-5-yyli]-8-kloori-6-fluori-1-[(1R,2S)-2-fluorisyklopropyyli]-4-okso-1,4-dihydrokinoliini-3-karboksyylihapon 3/2-hydraatin saamiseksi selektiivisesti
JPS6147820B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL8203688A (nl) Nieuwe kristalmodificatie van cimetidine, alsmede werkwijze voor de bereiding ervan.
KR20050108376A (ko) 시아노-이소벤조퓨란의 제조방법
US20050288330A1 (en) Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
HU194179B (en) Process for production of 1-/3',4'-dietoxi-benzil/-1,6,7-dietoxi-3,4-dihydro-izoquinolinine-teophilin-7-acetate and their new cristallic monohydrate
GB2097791A (en) Quaternary ammonium salt
US4889929A (en) Preparation of 1'-ethoxycarbonyl-oxyethyl esters of penicillins
SU1089092A1 (ru) Способ получени 3-(изохинолил-1)индола
DK175352B1 (da) Fremgangsmåde til fremstilling af 4-phenylpiperidinderivater
DE2225762B2 (de) Substituierte Fusarsäuren und Derivate derselben sowie Verfahren zur Herstellung derselben und Arzneimittel mit einem Gehalt derselben
JPS5852995B2 (ja) フルフラ−ル誘導体の製造法